First-in-human open-label dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors | NYU Langone Health

Go Back to All Clinical Trials

First-in-human open-label dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Malignant Solid Tumors
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1) histologically or cytologically confirmed non-CNS solid tumor that is metastatic or unresectable and for whom there is no available standard therapy likely to confer clinical benefit, or subjects who are not candidates for such available therapy, and for whom, in the opinion of the investigator, experimental therapy with GEN1046 may be beneficial.

You may not be eligible for this study if the following are true:

1) Participant has uncontrolled intercurrent illness, including but not limited to ongoing or active infection requiring intravenous treatment, symptomatic congestive heart failure, uncontrolled hypertension, and ongoing or recent evidence of significant autoimmune disease.